Westra W H, Baas I O, Hruban R H, Askin F B, Wilson K, Offerhaus G J, Slebos R J
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287-6971, USA.
Cancer Res. 1996 May 1;56(9):2224-8.
Atypical alveolar hyperplasia (AAH) is a potential precursor lesion from which lung adenocarcinomas arise and may be a good target for studying the early events of lung tumorigenesis. A common genetic alteration in lung adenocarcinomas is mutational activation of K-ras. To determine the timing of K-ras activation, we evaluated formalin-fixed and paraffin-embedded tissue samples of 41 AAHs and their paired lung neoplasms from 28 patients for codon 12 point mutations of the K-ras oncogene. K-ras codon 12 mutations were detected using PCR followed by allele-specific oligonucleotide hybridization. Mutations were found in 16 (39%) of the 41 AAHs, 8 (42%) of the 18 adenocarcinomas, and none (0%) of the 5 lung neoplasms that were not adenocarcinomas. Of the 18 patients with both an AAH and a synchronous lung adenocarcinoma, 6 had K-ras mutation in the adenocarcinoma but not in the AAH, 6 had mutations in the AAH but not in the adenocarcinoma, 4 did not harbor mutations in either the AAH or the adenocarcinoma, and 2 had mutations in both their AAH and their synchronous adenocarcinoma. In just 1 of the 18 patients was the same K-ras mutation present in the AAHs and adenocarcinoma of the patient. The detection of independent activating point mutations in a cancer-causing gene points to the neoplastic nature of AAH and suggests that glandular neoplasms of the lung arise from a background of field cancerization.
非典型肺泡增生(AAH)是肺腺癌的一种潜在前驱病变,可能是研究肺肿瘤发生早期事件的良好靶点。肺腺癌常见的基因改变是K-ras的突变激活。为了确定K-ras激活的时间,我们评估了来自28例患者的41个AAH及其配对肺肿瘤的福尔马林固定石蜡包埋组织样本中K-ras癌基因第12密码子的点突变情况。采用聚合酶链反应(PCR)后进行等位基因特异性寡核苷酸杂交检测K-ras第12密码子突变。在41个AAH中的16个(39%)、18个腺癌中的8个(42%)检测到突变,而5个非腺癌的肺肿瘤均未检测到突变(0%)。在18例同时患有AAH和同步肺腺癌的患者中,6例腺癌中有K-ras突变而AAH中没有,6例AAH中有突变而腺癌中没有,4例AAH和腺癌均未检测到突变,2例AAH和同步腺癌中均有突变。18例患者中只有1例患者的AAH和腺癌存在相同的K-ras突变。在致癌基因中检测到独立的激活点突变表明AAH具有肿瘤性质,并提示肺腺性肿瘤起源于场癌化背景。